These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 22718839)

  • 21. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
    Oki Y; Westin JR; Vega F; Chuang H; Fowler N; Neelapu S; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale M; Younes A; Rodriguez MA; Orlowski RZ; Wang M; Ouzounian ST; Samaniego F; Fayad L
    Br J Haematol; 2013 Dec; 163(5):611-20. PubMed ID: 24117234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
    Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
    Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ
    J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
    Chang JE; Peterson C; Choi S; Eickhoff JC; Kim K; Yang DT; Gilbert LA; Rogers ES; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
    Br J Haematol; 2011 Oct; 155(2):190-7. PubMed ID: 21848883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
    Villa D; Hoster E; Hermine O; Klapper W; Szymczyk M; Bosly A; Unterhalt M; Rimsza LM; Ramsower CA; Freeman CL; Scott DW; Gerrie AS; Savage KJ; Sehn LH; Dreyling M
    Blood Adv; 2022 Sep; 6(18):5285-5294. PubMed ID: 35439293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
    Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
    Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
    Gianni AM; Magni M; Martelli M; Di Nicola M; Carlo-Stella C; Pilotti S; Rambaldi A; Cortelazzo S; Patti C; Parvis G; Benedetti F; Capria S; Corradini P; Tarella C; Barbui T
    Blood; 2003 Jul; 102(2):749-55. PubMed ID: 12663455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
    Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
    van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
    Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
    Tam CS; Khouri IF
    Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
    Houot R; Le Gouill S; Ojeda Uribe M; Mounier C; Courby S; Dartigeas C; Bouabdallah K; Alexis Vigier M; Moles MP; Tournilhac O; Arakelyan N; Rodon P; El Yamani A; Sutton L; Fornecker L; Assouline D; Harousseau JL; Maisonneuve H; Caulet-Maugendre S; Gressin R;
    Ann Oncol; 2012 Jun; 23(6):1555-61. PubMed ID: 22012966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
    Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J; Inwards DJ; Witzig TE; Ansell SM; Allmer C; Slager SL; Cohen JB; Martin P; Cerhan JR; Nowakowski GS
    Blood Adv; 2022 Feb; 6(4):1350-1360. PubMed ID: 34662895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
    Takasaki H; Hashimoto C; Takemura S; Motomura S; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Jan; 51(1):57-62. PubMed ID: 20134141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
    Gressin R; Caulet-Maugendre S; Deconinck E; Tournilhac O; Gyan E; Moles MP; El Yamani A; Cornillon J; Rossi JF; Le Gouill S; Lepeu G; Damaj G; Celigny PS; Maisonneuve H; Corront B; Vilque JP; Casassus P; Lamy T; Colonna M; Colombat P;
    Haematologica; 2010 Aug; 95(8):1350-7. PubMed ID: 20220059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.